Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwCLL 2019 | Novel combination therapies in CLL

Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, speaking at the 18th International Workshop on Chronic Lymphocytic (iwCLL) Biennial Meeting, held in Edinburgh, UK. Davids speaks on achieving measurable residual disease (MRD( negativity through novel combination therapies, touching on current treatment options for Richter’s syndrome.